Citations

Clear

9 citation(s) found for "Liu, Ming".

Transformable Renal Cancer Targeted Responsive Nanopeptide Probes Effectively Inhibit Renal Cancer Progression and Metastasis by Inhibiting Renal Blood Vessels and Cancer Cells
Kong, Bin , Wu, Xiu‐Hai, Li, Cong , Chen, Meiqun, Liu, Yuwen , Liu, Cunyao, Wang, Xinyue , Chen, Bogong, Zang, Jiahui, Jian, Lingrui, Shen, Jiachen , Yu, Jiaao, Wu, Qiang , Yang, Guang , Wang, Ziqi , Wang, Lu , Wang, Lu , Liu, Pan , Chen, Meiqun, Liu, Cunyao, Liu, Ming

Mayo Clinic

ACS Applied Materials & Interfaces | November 13, 2025 | Volume: 17 | Issue: 47 | Pages: 64232-64243

10.1021/acsami.5c16546 | PMID 41231680 Get It

Dual‐stream algorithms for dementia detection: Harnessing structured and unstructured electronic health record data, a novel approach to prevalence estimation
Liu, Ming , Carver, Alison , Rocca, Walter A. , Lu, Alicia , Siostrom, Kristy, Roberts, Helene E., Chong, Trevor T.‐J. , Murray, Anne M. , Ravipati, Tanya , O’Bree, Bridget , Collyer, Taya Annabelle , Beare, Richard , Andrew, Nadine E. , Ung, David , Ilomäki, Jenni , Bell, J. Simon , Thrift, Amanda G. , Sauver, Jennifer L. St. , Moran, Chris , Roberts, Helene, Srikanth, Velandai

Mayo Clinic

Alzheimer's & Dementia | May 6, 2025 | Volume: 21 | Issue: 5 | Pages: No page available

10.1002/alz.70132 | PMID 40325920 Get It

AbstractINTRODUCTIONIdentifying individuals with dementia is crucial for prevalence estimation and service planning, but reliable, scalable methods are lacking. We developed novel set algorithms using both structured and unstructured electronic health record (EHR) data, applying Diagnostic and Statistical Manual of Mental Disorders criteria for dementia case identification.METHODSOur cohort (n = 1082) included individuals aged ≥ 60 with dementia identified through specialist clinics and a comparison group without dementia. Clinicians from Australia and the United States informed predictor selection. We developed algorithms through a biostatistics stream for structured data and a natural language processing (NLP) stream for text, synthesizing results via logistic regression.RESULTSThe final structured model retained 16 variables (area under the receiver operating characteristic curve [AUC] 0.853, specificity 72.2%, sensitivity 80.6%). NLP classifiers (logistic regression, support vector machine, and random forest models) performed comparably. The final, combined model outperformed all others (AUC = 0.951, P < 0.001 for comparison to structured model).DISCUSSIONEmbedding text‐derived insights within algorithms trained on structured medical data significantly enhances dementia identification capacity.Highlights Algorithmic tools for detection of individuals with dementia are available; however, previous work has used heterogeneous case definitions which are not clinically meaningful, and has relied on proxies such as diagnostic codes or medications for case ascertainment. We used a novel, dual‐stream algorithmic development approach, simultaneously and separately modeling a clinically meaningful outcome (diagnosis of dementia according to specialized clinical impression) using structured and unstructured electronic health record datasets. Our clinically grounded case definition supported the inclusion of key structured variables (such as dementia International Classification of Disease codes and medications) as modeling predictors rather than outcomes. Our algorithms, published in detail to support validation and replication, represent a major step forward in the use of routinely collected data for detection of diagnosed dementia.
Association Between Hormone Levels and Retinopathy in Patients With Type 2 Diabetes: A Cross-Sectional Study
Fan, Yuxin , Lu, Yuezhu, Zhu, Yun , Yan, Hua , Zhou, Fengqi, Meng, Yu , Yang, Xueli , Liu, Ming Rong , Zhou, Fengqi , Wang, Qihua

Mayo Clinic

Translational Vision Science & Technology | February 12, 2025 | Volume: 14 | Issue: 2 | Pages: 17

10.1167/tvst.14.2.17 | PMID 39937169 Get It

Abstract 188: An Atypical Cause of Subarachnoid Hemorrhage
Hass, Reece M. , Padilla, H., Mustafa, R., Liu, Ming

Mayo Clinic

Stroke: Vascular and Interventional Neurology | January 15, 2025 | Volume: 4 | Issue: S1 | Pages: No page available

10.1161/svin.04.suppl_1.188 Get It

Abstract 201: Atrial‐Esophageal Fistula Associated Food Embolism
Hass, Reece M. , Padilla, H., Mustafa, R., Liu, Ming

Mayo Clinic

Stroke: Vascular and Interventional Neurology | January 15, 2025 | Volume: 4 | Issue: S1 | Pages: No page available

10.1161/svin.04.suppl_1.201 Get It

Pursuing dementia detection for better prevalence estimation with artificial intelligence and traditional modelling techniques in electronic health data
Liu, Ming , Rocca, Walter A. , Lu, Alicia , Siostrom, Kristy, Roberts, Helene E., Kennedy, John Clark, Collyer, Taya Annabelle , Beare, Richard , Andrew, Nadine E. , Ilomäki, Jenni , Bell, J. Simon , Sauver, Jennifer L. St. , Thrift, Amanda G. , Ung, David , Moran, Chris , Roberts, Helene, Le, Elizabeth , Kennedy, John Clark, Srikanth, Velandai

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S7 | Pages: No page available

10.1002/alz.090057 Get It

AbstractBackgroundPopulation dementia prevalence is traditionally estimated using cohort studies, surveys, routinely‐collected administrative data, and registries. Hospital Electronic Health Records (EHRs) are comprised of rich structured and unstructured (text) clinical data that are underutilised for this purpose.We aimed to develop a suite of algorithms using routinely‐collected EHR data to reliably identify cases of dementia, as a key step towards incorporating such data in prevalence estimation. Towards this, we developed a novel predictive framework integrating data‐science and biostatistical methods.MethodTraining data were sourced via the National Centre for Healthy Ageing (NCHA) Data Platform, a linked, curated, EHR‐derived data warehouse. Individuals within the platform catchment aged >60 years with confirmed dementia were identified through hospital specialist dementia clinics. A comparison group of individuals aged >60years with EHR records without dementia was recruited from the community.A panel of clinical experts (Neurology, Geriatric Medicine) informed variable and concept selection and guided data cleaning efforts within both streams. Algorithms were developed via two work‐streams; a traditional biostatistical approach to fit logistic regression models using structured data elements, and a data science stream used Natural Language Processing (NLP) to fit models to the unstructured (text) parts of the EHR, for the same individuals.ResultOf 568 individuals (362 with dementia), 434 had clinical notes available. In the data science stream using unstructured data, among a range of NLP derived models, the Random Forest classifier performed best in assigning dementia status, with Area Under the Curve (AUC) 0.95, specificity 90.2% and sensitivity 88.4%. In the biostatistics stream, 15 structured variables were included in the final model, covering demographics, health service attendance, medications, and ICD‐10 Codes, with AUC 0.94, specificity 85.9% and sensitivity 85.6%.ConclusionArtificial intelligence techniques applied to unstructured electronic health data and guided by human clinical expertise may be powerful tools in capturing the presence of dementia, at least comparable to traditional techniques using structured data, and conferring practical and scientific advantages for dementia prevalence estimation. Future validation is required in less crisply delineated real‐world settings.
Abstract PD6-14: Analysis of DNA repair deficiency biomarkers as predictors of response to the PD1 inhibitor pembrolizumab: Results from the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer
Sanil, Ashish, Singhrao, Ruby , Investigators, I-SPY 2 TRIAL, Asare, Smita , Berry, Donald A. , Esserman, L., Veer, Laura van ‘t , Nanda, Rita , Yau, Christina , Wolf, Denise M. , Swigart, Lamorna Brown , Hirst, Gillian L. , Investigators, I-SPY 2 TRIAL, DeMichele, Angela , Veer, Laura J. van’t , Liu, Ming , Yee, Douglas

Mayo Clinic

Cancer Research | February 15, 2018 | Volume: 78 | Issue: 4_Supplement | Pages: PD6-14-PD6-14

10.1158/1538-7445.sabcs17-pd6-14 Get It

Abstract Background: Pembrolizumab (P), an anti-PD-1 immune checkpoint inhibitor, has been approved for treatment of microsatellite instability-high and mismatch repair deficient cancers. In I-SPY 2, patients were randomized to receive standard chemotherapy alone or in combination with an experimental agent. P was one of the experimental agents evaluated in HER2- patients in I-SPY 2 and graduated in the TN, HR+HER2-, and HER2- signatures. We hypothesize that a combination of two signatures predicting response to veliparib/carboplatin therapy in I-SPY 2 [MammaPrint High2 (MP2)/PARPi7-high] and reflecting DNA damage repair deficiency, may also predict response to P. In addition, we also tested 9 gene expression signatures reflecting different aspects of DNA damage and repair: FA, MMR, BER, HR, TLS, NER, NHEJ, DR, and DNA damage sensing (DDS) pathways. Methods: Data from 249 patients (P: 69 and controls: 180) were available. Pre-treatment biopsies were assayed using Agilent gene expression arrays. All I-SPY 2 qualifying biomarker analyses follow a pre-specified analysis plan. We used logistic modeling to assess biomarker performance. A biomarker is considered a specific predictor of P response if it associates with response in the P arm but not the control arm, and if the biomarker x treatment interaction is significant (likelihood ratio test, p&lt;0.05). This analysis is also performed adjusting for HR status as a covariate, and within receptor subsets, sample size permitting. For successful biomarkers, we use Bayesian modeling to estimate the pCR rates of 'predicted sensitive' patients in each arm. Our statistics are descriptive rather than inferential and do not adjust for multiplicities of other biomarkers outside this study. Results: MP2 status associates with pCR in P (OR=7.7; p=0.00021), but also to a lesser extent in the control arm (OR=2.4:p=0.045), with an OR ratio of 3.3 which trends toward significance, even after adjusting for HR status (LR p=0.083). A majority of TN patients are MP2; and TN/MP2 patients have an estimated pCR rate of 67% in P (vs. 23% in control). Although only ~30% of HR+HER2- patients were MP2, their estimated pCR rate in P is 61%, compared to 29% in unselected HR+/HER2- patients. PARPi7 predicted response in the P arm only in the HR+HER2- group (LR p= 0.025), but not in the population as a whole or the TN subtype. Combining MP2 and PARPi7 into MP2/PARPi7-high did not improve performance over MP2 as a single biomarker. Of the 9 DDR pathway signatures tested, both BER and DDS associate with pCR in P, but only DDS (which includes ATM, ATR, CHEK1-2) associates with pCR in the P arm (LR p=0.00029), and not the control arm (LR p=0.53), with a significant interaction with treatment (LR p=0.0064) that retains significance in a model adjusting for HR status. When dichotomized to optimize the biomarker x treatment interaction, the estimated pCR rate is 75% in P vs 18% in control, in the DDS+ subset. Conclusion: In this small study, MP2 status and a DNA damage sensing pathway but not the PARPi7 or other repair pathways show promise as predictive biomarkers for immune checkpoint inhibition therapy in breast cancer. Citation Format: Yau C, Wolf D, Brown-Swigart L, Hirst G, Sanil A, Singhrao R, I-SPY 2 TRIAL Investigators, Asare S, DeMichele A, Berry D, Esserman L, van 't Veer L, Nanda R, Liu M, Yee D. Analysis of DNA repair deficiency biomarkers as predictors of response to the PD1 inhibitor pembrolizumab: Results from the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD6-14.
Abstract P6-12-04: Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer
Forero‐Torres, Andres , Specht, Jennifer M. , Weise, Amy, Burris, Howard A. , Liu, Ming, Krop, Ian E. , Mita, Monica , Modi, Shanu , Miller, Kathy D. , Pusztai, Lajos , Kostic, Aleksandar David , Li, Michael , Specht, Jennifer

Mayo Clinic

Cancer Research | March 1, 2017 | Volume: 77 | Issue: 4_Supplement | Pages: P6-12-04-P6-12-04

10.1158/1538-7445.sabcs16-p6-12-04 Get It

Abstract Background LIV-1, a transmembrane protein and downstream target of STAT3, is highly expressed in breast cancer cells. It is associated with lymph node involvement and metastatic progression. SGN-LIV1A is an anti-LIV-1 antibody conjugated via a protease-cleavable linker to monomethyl auristatin E (MMAE). Upon binding to cell-surface LIV-1, SGN-LIV1A is internalized and releases MMAE, which binds to tubulin and induces G2/M arrest and apoptosis. Methods This is an ongoing, phase 1 dose-escalation study evaluating safety, tolerability, pharmacokinetics, and antitumor activity of SGN-LIV1A (q3 wks IV) in women with LIV-1-positive, unresectable, locally advanced or metastatic breast cancer (LA/MBC) (NCT01969643). Patients (pts) with measurable disease and ≥2 prior cytotoxic regimens for LA/MBC were eligible. Pts with ≥Grade 2 neuropathy were excluded. Response was assessed per RECIST v1.1; pts with stable disease (SD) or better could continue treatment until disease progression or intolerable toxicity. At completion of dose escalation in hormone receptor-positive/HER2-negative (HR+/HER2–) and triple-negative (TN) pts, expansion cohorts were opened to further evaluate safety and antitumor activity of monotherapy in TN pts and combination therapy with trastuzumab (Tz) in HER2-positive (HER2+) pts. Pre- and post-treatment tumor biopsies were done to evaluate LIV-1 expression and other correlative endpoints. Results To date, 39 pts (18 HR+/HER2–, 21 TN) have received a median of 3 cycles (range, 1–10) of SGN-LIV1A monotherapy at doses of 0.5–2.8 mg/kg. Median age was 57 yrs (range, 33–79). At baseline, pts had a median of 4 prior cytotoxic regimens for LA/MBC (range, 2–8); 36 had visceral disease and 25 had bone involvement. No dose-limiting toxicities (DLT) occurred in 19 DLT-evaluable pts; maximum tolerated dose was not exceeded at 2.8 mg/kg. Treatment-emergent adverse events (AEs) reported in ≥30% of pts were: fatigue (64%), nausea (54%), alopecia (46%), decreased appetite (41%), constipation (39%), neutropenia (33%), and vomiting (31%). Peripheral neuropathy was reported in 9 pts (23%). Most AEs were Grade 1/2, except neutropenia (all ≥Grade 3). Four pts discontinued treatment due to AEs (acute respiratory distress syndrome, nausea, pneumonia, tachycardia). In dose escalation, modest activity was observed in 17 efficacy evaluable (EE) HR+/HER2- pts, with a disease control rate (DCR) of 59% (10 SD), including 1 pt with SD≥24 wks. Among the 17 EE TN pts (dose escalation plus cohort expansion), the overall response rate (ORR) was 41% (7 PR), DCR was 82% (7 PR, 7 SD) and clinical benefit rate (CBR=OR+SD≥24 wks) was 53% (9 pts). For TN pts, median PFS was 17.1 wks (95% CI: 6.0, 18.4); 6 pts remain on treatment. Of 281 MBC tumor samples evaluated for LIV-1, 93% were positive; 81% had moderate-to-high expression (H-score ≥100). Conclusions LIV-1 is expressed in almost all MBC tumors. SGN-LIV1A monotherapy has been generally well tolerated and shown encouraging antitumor activity in heavily pretreated TN MBC, with a PR rate of 41% and a CBR at ≥24 wks of 53%. Response duration data continue to evolve. Enrollment continues in the TN monotherapy expansion cohort and the HER2+ combination cohort with Tz. Citation Format: Forero-Torres A, Modi S, Specht J, Miller K, Weise A, Burris III H, Liu M, Krop I, Pusztai L, Kostic A, Li M, Mita M. Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-12-04.
Differential Docking of High-Affinity Peptide Ligands to Type A and B Cholecystokinin Receptors Demonstrated by Photoaffinity Labeling
Dong, Maoqing , Pinon, Delia I., Liu, Guang‐Ming , Miller, Laurence J.

Mayo Clinic

Biochemistry | April 26, 2005 | Volume: 44 | Issue: 17 | Pages: 6693-6700

10.1021/bi050130q | PMID 15850403 Get It